Skip to main content

Michael Lotze, MD, PhD

Michael Lotze, MD, PhD

Professor of Surgery, Immunology, and Bioengineering
University of Pittsburgh Cancer Institute
University of Pittsburgh School of Medicine
Assistant Vice Chancellor, Sponsored Training Grants
University of Pittsburgh Schools of the Health Sciences
Pittsburgh, PA

Related Videos

What kinds of reporters were use to confirm and observe the differentiated biological and side effect profiles associated with the current dosing strategies for nemvaleukin?

What kinds of reporters were use to confirm and observe the differentiated biological and side effect profiles associated with the current dosing strategies for nemvaleukin?

Can you clarify: (a) what the novel, engineered cytokine fusion protein nemvaleukin is; (b) its differentiating biological properties; (c) MOA; and (d) its effects on immune-centric cell subpopulations such as Tregs, CD8+ and natural killer cells?

Can you clarify: (a) what the novel, engineered cytokine fusion protein nemvaleukin is; (b) its differentiating biological properties; (c) MOA; and (d) its effects on immune-centric cell subpopulations such as Tregs, CD8+ and natural killer cells?

How has novel engineering of nemvaleukin produced a side effect profile that differs from hrIL-2 and or altering IL-2? What implications might this have for an expanded role for nemvaleukin in tumors other than mucosal melanoma and ovarian cancer?

Looking forward, what types of cancer do you think might prove to be amenable to nemvaleukin therapy?

Looking forward, what types of cancer do you think might prove to be amenable to nemvaleukin therapy?

In what specific ways is nemvaleukin distinct from other cytokines, and what ways does its novel engineering allow it to take on unique mechanistic properties that differentiates it from all cytokines, not just IL-2?

In what specific ways is nemvaleukin distinct from other cytokines, and what ways does its novel engineering allow it to take on unique mechanistic properties that differentiates it from all cytokines, not just IL-2?

Can you kindly introduce yourself to your immuno-oncology colleagues and share with us your scientific and clinical interests and experience focused on cytokines and their role in immunotherapy for cancer?

Can you kindly introduce yourself to your immuno-oncology colleagues and share with us your scientific and clinical interests and experience focused on cytokines and their role in immunotherapy for cancer?

Why has IL-2 emerged as a foundational cytokine in cancer immunotherapy? And specifically, what is its pivotal biological role in the complex networks of cell-cell and paracrine signaling/crosstalk in the tumor immune microenvironment?

Why has IL-2 emerged as a foundational cytokine in cancer immunotherapy? And specifically, what is its pivotal biological role in the complex networks of cell-cell and paracrine signaling/crosstalk in the tumor immune microenvironment?

Given the current state of knowledge about nemvaleukin, at least based on the dose escalation phase 1 ARTISTRY-1 trial, what is your assessment of how this novel cytokine fusion protein will—or can—be positioned, combined, and/or sequenced?

Given the current state of knowledge about nemvaleukin, at least based on the dose escalation phase 1 ARTISTRY-1 trial, what is your assessment of how this novel cytokine fusion protein will—or can—be positioned, combined, and/or sequenced?

Why, when the world woke up to the fact that cancer was also “a disease of the immune response,” was there, by extension intense interest in a cytokine fusion protein such as nemvaleukin? And what was the novel aspect of its engineering?

Why, when the world woke up to the fact that cancer was also “a disease of the immune response,” was there, by extension intense interest in a cytokine fusion protein such as nemvaleukin? And what was the novel aspect of its engineering?